These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1615101)

  • 21. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early treatment events and prediction of response to neuroleptics in schizophrenia.
    Awad AG; Hogan TP
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):585-8. PubMed ID: 2868492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
    Kramer MS; Vogel WH; DiJohnson C; Dewey DA; Sheves P; Cavicchia S; Little P; Schmidt R; Kimes I
    Arch Gen Psychiatry; 1989 Oct; 46(10):922-8. PubMed ID: 2679483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
    Newcomer JW; Miller LS; Faustman WO; Wetzel MW; Vogler GP; Csernansky JG
    Br J Psychiatry; 1994 Jun; 164(6):834-8. PubMed ID: 7952993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia.
    Becker RE
    Am J Psychiatry; 1983 Feb; 140(2):208-11. PubMed ID: 6336916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.
    Kelley ME; van Kammen DP; Allen DN
    Am J Psychiatry; 1999 Mar; 156(3):406-11. PubMed ID: 10080556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M; Hashimoto T; Takamatsu T; Maeda K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
    Bartkó G; Frecska E; Horváth S; Zádor G; Arató M
    Acta Psychiatr Scand; 1990 Dec; 82(6):408-12. PubMed ID: 1981296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of schizophrenic patients relapsed on and off medication.
    Bartkó G; Mayláth E; Herczeg I
    Psychiatry Res; 1987 Nov; 22(3):221-7. PubMed ID: 2893403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-responsive symptoms during early neuroleptic treatment.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
    Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
    Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to antipsychotic medication: the doctor's and the consumer's view.
    Van Putten T; May PR; Marder SR
    Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life in schizophrenia: insight and subjective response to neuroleptics.
    Browne S; Garavan J; Gervin M; Roe M; Larkin C; O'Callaghan E
    J Nerv Ment Dis; 1998 Feb; 186(2):74-8. PubMed ID: 9484306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.